-
Guest Voice: Navigating the windy road of rare disease specialists
Living with a rare disease is incredibly complex, with countless layers to navigate. Managing daily
-
Capricor Therapeutics Announces New PDUFA Date for Deramiocel
Capricor Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has lifted the
-
MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are
-
Capricor announces the FDA to review deramiocel for Duchenne by August 2026
As an early funder of Capricor Therapeutics, CureDuchenne is pleased to share that the FDA
-
Edgewise Therapeutics, a CureDuchenne funded company, announces positive long-term Sevasemten data in Becker muscular dystrophy patients.
Edgewise Therapeutics, a CureDuchenne funded company, today announced positive long-term Sevasemten data that demonstrated sustained
-
Edgewise Announces Positive Long-Term Sevasemten Data
Edgewise Therapeutics, Inc. has shared long-term data from its MESA open-label extension study of sevasemten
-
2026 MDA Clinical & Scientific Conference Opening Highlights the Power of Collaboration
Sharon Hesterlee, PhD, MDA President and CEO On March 9, Sharon Hesterlee, PhD, MDA President
-
PPMD and FED Announce 2026 Advocacy Leadership Awards Honoring Bipartisan Champions in Congress
PPMD, in partnership with the Foundation to Eradicate Duchenne (FED), is pleased to announce Representative
-
‘The Wonder Years’ were the ‘worry years’ before my MD diagnosis
I recently found myself rummaging through a very old collection of things from my childhood
-
Advocates Unite in Washington to Advance Duchenne and Becker Policy, Mark 25th Anniversary of MD-CARE Act
PPMD heads to Capitol Hill today with a group of more than 120 Duchenne and
